Impact of immunosuppressants on COVID-19 vaccine response
Dr Daniel Streetman considers whether immunosuppressants can reduce the response to COVID-19 vaccines
5th July 2021
Web Exclusives
Deeper digitisation
Three ways technology can support NHS workers today, tomorrow and into the future
24th June 2021
Green shoots, grey hairs and TLC
How start-ups can bridge the gap and grow with venture capital support
18th June 2021
Weathering the COVID storm
Four ways pharma must embrace tech to weather the COVID storm
18th June 2021
The promise of new science
New science shines a bright light on the future of UK biopharma
18th June 2021
How a data fabric can accelerate clinical trials
Clinical trials must deal with extreme amounts of diverse data which are generated across several institutions. A flexible data architecture can help shorten the journey to approval and distribution
14th May 2021
Safety first
Professor Saad Shakir on the gap in public knowledge about routine drug safety and pharmacovigilance activity
13th May 2021
Smart People: Jeff Elton
Jeff Elton, chief executive of ConcertAI, talks to PharmaTimes about the pandemic's impact on oncology trials in the US
11th May 2021
Predicting risk
How pharma can use natural language processing for drug safety predictions
11th May 2021
Getting the brand story right
Optimising value propositions for payers – some simple rules
10th May 2021
Consumer vision: the decade ahead
A theme of the decade that health chief marketing officer's can’t afford to ignore
7th May 2021
Flu is ever evolving and so are we
There is no doubt that flu will return, but we are prepared for it, says Beverly Taylor
6th May 2021
Optimising regulatory information management
Extracting the value from data integration
30th April 2021
COVID and the growing threat of counterfeit medicines
Has the pandemic created a perfect storm for counterfeit pharmaceuticals?
29th April 2021
